Company news

Esperion Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Esperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure

September 30, 2026

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

May 26, 2026

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

May 13, 2026

Esperion to be Acquired by ARCHIMED

May 1, 2026

Esperion to Report First Quarter 2026 Financial Results on May 7

April 23, 2026

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

April 1, 2026

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

April 1, 2026

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

March 30, 2026

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026

March 29, 2026

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

March 16, 2026

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

March 15, 2026

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 9, 2026

Correction: HLS Therapeutics Inc.

March 5, 2026

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst

March 4, 2026

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

March 2, 2026

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

February 23, 2026

Esperion to Participate in The 2026 Citizens Life Sciences Conference

February 17, 2026

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

February 17, 2026

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 11, 2026

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

January 11, 2026

Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes

December 19, 2025

Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

November 21, 2025

Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference

November 19, 2025

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

November 18, 2025

Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025

November 10, 2025

Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update

November 6, 2025

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

November 4, 2025

Esperion to Participate in Jefferies Global Healthcare Conference - London

November 3, 2025

Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2: 00 p.m. ET.

October 28, 2025

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

October 27, 2025

Esperion to Report Third Quarter 2025 Financial Results on November 6

October 23, 2025

Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis

October 16, 2025

Esperion Announces Pricing of Public Offering of Common Stock

October 7, 2025

Esperion Announces Proposed Public Offering of Common Stock

October 7, 2025

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

October 3, 2025

Oritain Extends Cutting-Edge Origin Verification to Leather for EUDR Readiness

September 23, 2025

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

September 19, 2025

Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

August 29, 2025

Esperion to Participate in Upcoming September Investor Conferences

August 26, 2025

HLS Therapeutics Announces Q2 2025 Financial Results

August 14, 2025

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

August 5, 2025

Esperion to Report Second Quarter 2025 Financial Results on August 5

July 22, 2025

Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

July 8, 2025

Esperion Appoints Craig Thompson to Board of Directors

July 1, 2025

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

June 2, 2025

Esperion to Participate in Upcoming June Investor Conferences

May 20, 2025

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 12, 2025

Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference

May 9, 2025

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 8, 2025

Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.